We Don’t Know if the Babies Born From Mitochondrial Replacement Therapy Will Still Develop Mitochondrial Disease
By Katherine Drabiak,
Journal of Medical Ethics Forum
| 08. 07. 2025
Adapted from Mitochondrial DNA at
National Human Genome Research Institute
Recently, media outlets around the world have been reporting on children born from pronuclear genome transfer (sometimes called “3-parent IVF,” “mitochondrial donation” or “mitochondrial replacement therapy”) at Newcastle Fertility Center in the United Kingdom. Twenty-two women underwent the procedure, which resulted in eight children, who now range in age from six months to over two years old. Some have called it an “important milestone” and a “pioneering” technique to spare children from fatal disease.
New England Journal of Medicine published two articles describing the process, and the follow-up exams of the children. This is not the first time mitochondrial replacement therapy (MRT) has been used to create children. In 2016, a U.S. physician traveled to Mexico to create an infant using MRT; and clinics in Greece, Ukraine and Cypress advertise MRT as a “treatment” for infertility.
MRT is not a curative therapy, or simply a new type of IVF. MRT is an experimental procedure that creates an embryo using the DNA from three...
Related Articles
By Maggie Astor, The New York Times | 06.23.2026
Every year, patients undergo millions of in vitro fertilization procedures worldwide. Only a minority result in a live birth.
In an effort to improve the odds, scientists have developed an array of “add-ons” that could in theory identify the most...
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Philip Ball , Nature | 06.17.2026
Our genomes are full of mutations that have the potential to damage our health or even kill us. Yet most of them rarely cause problems. Why? It’s partly thanks to a family of proteins that mask, or ‘buffer’, the ill...